HTHikmet Gülşah Tanyıldız

Hikmet Gülşah Tanyıldız

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hikmet Gülşah Tanyıldız has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Metabolic Imaging of Pediatric Head and Neck Rhabdomyosarcoma: From Initial Staging to Treatment Response Assessment with F18-FDG PET/CT

    by Emine Göknur Işık, Dılşat Fırat Arslan, Şifa Şahin, Hikmet Gülşah Tanyıldız

    Objective: To describe the staging and treatment-response characteristics of F18-FDG PET/CT in pediatric head and neck rhabdomyosarcoma (RMS) and their relationship with pretreatment stage and outcome.Materials and Methods: We retrospectively reviewed 21 pediatric patients (≤18 years) with head and neck RMS who underwent F18-FDG PET/CT. Pretreatment COG/IRS stage was confirmed in all patients (I = 9, II = 3, III = 8, IV = 1). Staging SUVmax was analyzed in 18 patients; 3 underwent postoperative-only PET/CT. Interval treatment-response PET/CT (n=15) was categorized as good/complete, minimal, or substantial residual response. Median follow-up was 23 months (range 9-92).Results: Median age was 5 years (range 2-17); 16 patients were male. Orbital tumors were the most common (38.1%), followed by parameningeal (33.3%) and non-parameningeal non-orbital sites (28.6%). Staging SUVmax increased with stage (3.5, 7.9, and 7.2 in stages I, II, and III; p=0.034; rho=0.55, p=0.019). Mortality was 62.5% in stage III versus 16.7% in stage I-II (p=0.062); the stage IV patient was alive. Among 15 patients with treatment-response imaging, 46.7% achieved good/complete response, 33.3% achieved minimal response, and 20% achieved substantial residual uptake; mortality did not differ by response tier (p=0.61).Conclusion: Pretreatment stage showed a trend toward association with outcome, with the highest mortality in stage III disease, and staging SUVmax correlated significantly with stage. Early metabolic response did not reliably predict outcome. F18-FDG PET/CT provides useful staging and treatment-response information but should be interpreted alongside clinical stage and close follow-up.

  • Open Access

    Dynamic Metabolic Parameters and Deauville Score on 18F-FDG PET/CT for Prognostic Assessment in Pediatric Burkitt Lymphoma

    by Emine Goknur Isik, Sifa Sahin, Duygu Has Simsek, Ebru Yilmaz, Sema Buyukkapu Bay, Rejin Kebudi, Seher Nilgun Unal, Hikmet Gulsah Tanyildiz

    Background/Objectives: 18F-FDG PET/CT is increasingly used in pediatric Burkitt lymphoma (BL) for staging and treatment response assessment, but data on quantitative prognostic markers remain limited. Methods: We retrospectively evaluated 33 children with pathologically confirmed BL who underwent baseline and end-of-treatment (EOT) 18F-FDG PET/CT between 2009 and 2024. SUVmax, metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were measured at baseline and EOT, and the Deauville score (DS) was assigned visually. Progression-free survival (PFS) and overall survival (OS) were estimated with the Kaplan–Meier method; receiver operating characteristic (ROC) analysis identified predictive thresholds. Results: Three-year and 5-year OS was 89.6%, and PFS was 90.1%. The percentage reduction in SUVmax from baseline to EOT (%ΔSUVmax) was the strongest predictor of survival (AUC = 0.94; optimal cutoff ≥ 73.6% reduction; sensitivity 100%, specificity 93%). Patients with an unfavorable EOT DS (4–5) had significantly lower OS than those with a favorable DS (1–3) (60.0% vs. 96.4%; log-rank p = 0.009). Baseline SUVmax, MTV, and TLG did not differ significantly by stage or splenic involvement. Given the small number of survival events (n = 3), the corresponding hazard ratios and confidence intervals should be regarded as exploratory and hypothesis-generating rather than definitive effect sizes. Conclusions: Dynamic metabolic response such as %ΔSUVmax and the EOT Deauville score are promising prognostic markers in pediatric BL. Given the small number of events, these findings warrant validation in larger, prospective cohorts.

  • Open Access

    Improving time to antibiotic administration in febrile neutropenia: A quality improvement initiative in a pediatric oncology inpatient unit

    by Yasin Yilmaz, Gozde Gul, Cansu Ceren Eryilmaz, Ece Melis Adalet Peker, Gulcan Erbas, Osman Kuleli, Sifa Sahin, Pinar Taspinar, Vildan Kocali, Gulsah Tanyildiz, et al.

    Objective: Febrile neutropenia (FN) is a medical emergency requiring prompt initiation of empirical antibiotic therapy. We aimed to evaluate the impact of a structured, unit-based quality improvement intervention on time to antibiotic administration (TTA) in hospitalized pediatric oncology patients. Materials and Methods: This single-center quality improvement study was conducted in a pediatric oncology inpatient unit. The intervention consisted of a structured educational program targeting healthcare professionals, including physicians and nurses. FN episodes were analyzed across pre-intervention, intervention, and post-intervention phases, and TTA was compared between these periods. Results: A total of 73 FN episodes in 40 patients were included. Median TTA decreased from 38 minutes in the pre-intervention phase to 32 minutes during the intervention phase and to 18 minutes in the post-intervention phase (p<0.001). The proportion of patients receiving antibiotics within 60 minutes increased from 77% to 100% (p=0.010). Conclusion: A structured, unit-based quality improvement intervention significantly reduced TTA in hospitalized pediatric oncology patients. These findings highlight the importance of system-level strategies in improving time-sensitive clinical processes in high-risk patient populations.

  • Open Access

    Antibiotic lock therapy for catheter-related bloodstream infections in pediatric hemato-oncology: a retrospective analysis

    by Besarta Kaçabeti, Remziye Semerci Şahin, Pınar Taşpınar, Gülcan Erbaş, Serap Karaman, Zeynep Karakaş, Ayper Somer, Selda Hançerli, Gülşah Tanyıldız

    This study aims to comprehensively evaluate the efficacy and safety of Antibiotic Lock Therapy (ALT) in pediatric patients and to better clarify its role in catheter management. This retrospective single-center study was conducted between October 2021 and October 2024. Of 53 eligible patients, 47 received ALT and constituted the primary analysis population for treatment outcomes; 6 patients underwent immediate catheter removal without ALT and were excluded from the ALT efficacy analysis. Demographic, clinical, and microbiological data from all patients were collected. A total of 70 catheter-related bloodstream infection (CRBSI) episodes were identified among 47 patients, corresponding to an incidence rate of 12.79 per 1,000 catheter-days. The most frequently isolated pathogens were coagulase-negative staphylococci (CoNS), followed by gram-positive bacilli and Klebsiella spp. Antibiotic Lock Therapy (ALT) was administered to 47 patients and was successful in 70.2% of these cases (33/47) (p = 0.038). Among patients who did not receive ALT and required catheter removal, Klebsiella spp. and methicillin-resistant CoNS (MRCoNS) were the predominant organisms associated with sepsis and infection. In patients requiring catheter removal despite receiving ALT, gram-negative organisms were the most common pathogens, followed by gram-positive bacilli. Notably, infections most frequently developed between days 11 and 45 of catheter use, indicating a critical high-risk window for catheter-related infections. Catheter-related infections remain a significant clinical challenge in pediatric hematology-oncology patients. Our findings suggest that ALT was associated with catheter retention in a considerable proportion of patients; however, given the retrospective design and potential for confounding by indication, this observation should be interpreted cautiously rather than as a definitive efficacy claim. The identification of a high-risk period between days 11 and 45 may support closer monitoring and earlier intervention. Further prospective studies with standardized selection criteria are required to validate and standardize the use of ALT in this vulnerable population.


  • Open Access

    Three locally invasive infantile fibrosarcoma cases treated with larotrectinib

    by Hikmet Gülşah Tanyıldız, Yasin Yılmaz, Doğa Dalay, Şifa Şahin, Serap Karaman, Ayşegül Ünüvar, Zeynep Karakaş, Deniz Tuğcu

    Background. Infantile fibrosarcoma is a rapidly growing soft tissue tumor, often managed by surgical resection, with chemotherapy and radiotherapy as additional options. Due to the high local aggressiveness and surgical morbidity, targeted therapies like larotrectinib can enhance quality of life and preserve organs, particularly in limb-threatening cases. Here, we present three cases where larotrectinib prevented mutilating surgeries. Cases. The first patient presented antenatally with a 75 x 48 mm oral floor mass, severely narrowing the airway. Surgery was unfeasible due to invasion of vital organs, and complications arose with conventional chemotherapy. Following detection of an ETV6-NTRK3 fusion, larotrectinib was initiated, resulting in complete regression after two years. The second patient had a 42 x 37 mm right-hand tumor confirmed as infantile fibrosarcoma, for which initial treatment suggested amputation. After identifying an ETV6-NTRK3 fusion and failing to respond to chemotherapy, larotrectinib led to significant regression by year two, preserving hand function. The third patient presented with a 56 x 55 mm right foot mass at birth. Chemotherapy proved ineffective, and larotrectinib was initiated due to an ETV6-NTRK fusion signal, ultimately achieving near total regression within one year and avoiding amputation. All three cases demonstrated successful outcomes with targeted therapy. Conclusions. These cases emphasize the importance of advanced molecular studies, like next-generation sequencing, for childhood tumors and integrating research with clinical trials. tropomyosin receptor kinase inhibitor larotrectinib may offer a safe and effective alternative to chemotherapy for NTRK fusion-positive, metastatic, or unresectable tumors.


  • Open Access

    Neurodevelopmental Effects of Propranolol Treatment During Infancy in Infantile Hemangioma Patients

    by Cenk Baykan, Melike Mete Çiftseven, Gonca Keskindemirci, Öykü Özbörü Aşkan, Alev Bakır Kayı, Serap Karaman, Ayşegül Ünüvar, Deniz Tuğcu, Emine Gulbin Gokcay, Merve Arslan, et al.

    Introduction and Aim: Propranolol is an effective treatment option for infantile hemangiomas, but there is still insufficient information about neurodevelopmental side effects of propranolol. In our study, the neurodevelopmental levels of infantile hemangioma patients receiving propranolol treatment were examined using the Bayley-III test. Method: In our single-center, cross-sectional study, patients were recruited between 1 January 2020 and 31 December 2023. In total, 40 children (n1) diagnosed with hemangioma who received propranolol treatment and 31 children (n2) who were only under observation were included. A control group of 31 healthy children (n3) matched for age and gender was also included. The demographic, clinical, perinatal, and postnatal characteristics of the total 102 children were recorded from their medical records. Neurodevelopmental levels were assessed with the Bayley-III test. The significance level was set at (p < 0.05). Results: The Bayley-III test composite and percentile scores were used to evaluate the neurodevelopmental levels. Significant differences in motor functions were found between the treated and untreated groups compared to the healthy control group (p = 0.006 and p = 0.006). However, no significant differences were found in cognitive, language, and social-emotional skills. Cognitive, language, and motor functions were associated with maternal education level, and additionally, cognitive functions were also associated with paternal education level. Conclusions: Propranolol has a relatively safer side effect profile, and therefore, it has been described as a safe agent. In our study, no significant effect of propranolol on neurodevelopment was observed. The difference in motor skills shown was mainly between the healthy control group (n3) and the treated and untreated group (n1 and n2), which led to the conclusion that the relevant difference could be due to factors other than propranolol itself.


  • Open Access

    Clinical Presentation, Treatment, and Outcomes of Pediatric Brain Tumors: A 5-Year Single-Center Experience in Istanbul

    by Hikmet Gulsah Tanyildiz, Yasin Yılmaz, Şifa Şahin, Serap Karaman, Aysegul Unuvar, Deniz Tugcu, Zeynep Karakas

    Background: Brain tumors are the most common solid tumors in childhood. With the help of increased clinical awareness, improvements in imaging methods, and the identification of molecular characteristics, advances have been made in both diagnosis and treatment. Objectives: In our study, we aimed to discuss the childhood brain tumor cases followed in our clinic, along with their clinical and epidemiological features and treatment outcomes. Methods: The study group comprised children younger than 18 years old who were followed in the Pediatric Hematology and Oncology Clinic of Istanbul Medical Faculty and diagnosed with a brain tumor over the past 5 years (2018 - 2023). Symptoms, age at diagnosis, treatment options (surgery, radiotherapy, chemotherapy), and side effects were reviewed retrospectively. Results: Thirty children were diagnosed with brain tumors. Of the patients, 14 (47%) were male and 16 (53%) were female. The mean age of the children was 8.8 ± 3.1 years, and the mean age at diagnosis was 65.6 ± 37.7 months. The most common symptom was vomiting (40%). The mean duration between the onset of symptoms and diagnosis was 3.8 months, with a median of 1 month. Of the patients, 60% were diagnosed with glial tumors and 40% with non-glial tumors. Gross total resection (GTR) was performed in 26% of patients, subtotal resection (STR) in 37%, and 37% of patients did not undergo surgery. Seventy-seven percent of the patients received chemotherapy, and 57% received radiotherapy. Of the patients, 57% were considered responsive to treatment (complete/partial), 30% had stable disease, and 13% had progressive disease. The overall brain tumor mortality rate in our clinic was 13%. While 73% of our 26 patients had no or mild neurological deficits, 27% had moderate to severe disabilities (gait impairment, hearing impairment, visual impairment). Conclusion: Although the sample size was limited, it may be speculated that the surgery rate was low and long-term side effects were notable. Insufficient surgical resection can affect the treatment response and increase the risk of neurological sequelae and functional impairment. Molecular profiling should be expanded, and a palliative care team should be involved as early as possible to address long-term side effects and improve the quality of life for patients.


  • Open Access

    Evaluation of late effects during a 21-year follow-up of pediatric Hodgkin lymphoma survivors: Experience of a pediatric cancer center in Turkey, as a developing country model

    by Nurdan Tacyildiz, Hatice M Cakmak, Emel Unal, Handan Dincaslan, Gulsah Tanyıldız, Sonay İ Özdemir, Ömer Kartal, Yasin Yılmaz, Gulsan Yavuz, Işınsu Kuzu

    Background: Long-term survivors of Hodgkin lymphoma (HL) are at risk of developing a range of late effects, with a second malignant neoplasm and cardiovascular diseases being the leading causes of death in these patients. The present study aims to evaluate the late side effects in children with HL. Materials and Methods: Out of 53 HL patients, we assessed the long-term effects of childhood HL survivors (HLSs; n = 50) diagnosed between 1998 and 2019. Patient data related to chronic health conditions, and sociodemographic characteristics were compared with their siblings ( n = 56). Results: The cumulative overall survival (OS) at 1, 5, and 10 years from diagnosis was 98.1 ± 1.9%, 93.3 ± 3.8%, and 93.3 ± 3.8%, respectively. Groups of HLSs and their siblings were matched according to age and gender. Compared with siblings, survivors had will be changed as ‘a higher frequency of nephrotoxicity ( P = 0.02)’, cardiotoxicity ( P = 0.12), thyroid dysfunction ( P = 0.001), health care service usage ( P < 0.01), limitation of physical function ( P = 0.01), and pulmonary disease ( P = 0.01). The control group of siblings had a higher incidence of marital status ( P < 0.01), parenthood ( P = 0.01), and smoking habit ( P = 0.03). Thyroid dysfunction was associated with neck radiotherapy ( P < 0.01). No secondary neoplasm was detected. In relapsed, refractory setting ( n = 10), autologous transplantation ( n = 9) is performed after a complete remission. Brentuximab vedotin with or without bendamustine and rituximab is also used in selected patients. Conclusions: Increased number of chronic health conditions and social problems point to the significance of long-term follow-up of HLSs. We are currently preparing a survivorship guideline appropriate for Turkey’s conditions. Implications for Cancer Survivors: Renal, heart, pulmonary impairment, thyroid dysfunction, limitation in physical functioning, and deterioration in social status (marriage, having children, education).


  • The investıgatıon of symptoms and therapy delay in children with cancer during COVID pandemic: A center experience

    by Yasin Yilmaz, Gülşah Tanyildiz, Sifa Sahin, Cansu Ceren Eryilmaz, Mustafa Bilici, Serap Karaman, Deniz Tugcu, Aysegul Unuvar, Zeynep Karakas

    Objective: The COVID-19 pandemic had a worldwide effect on people as well as on pediatric patients with cancer. This effect also caused cancer therapy plan alterations. In this study, we aimed to investigate pediatric patients with cancer who were diagnosed as having COVID-19 infections and the alterations in treatment plans. Methods: Pediatric patients with cancer who were followed up in XXX Medical Faculty Pediatric Hematology and Oncology Outpatient Clinic and were diagnosed as having COVID-19 between March 2020 and March 2022 were retrospectively analyzed. Results: A total of 28 patients were diagnosed as having a COVID-19 infection. Forty-three percent of the patients had leukemia, and 57% had solid tumors. More than half (58%) of the patients had mild COVID-19 symptoms. Sixteen (57%) patients had a therapy delay because of COVID-19 infections. The mean therapy delay day was 5.8 ± 2.9 (median: 5 days). Hematologic malignancy (leukemia) had a delay rate of 33% in therapy, and it was 75% in solid tumors. Conclusion: The COVID-19 pandemic affected all people as well as pediatric patients with cancer. The rate of delay in therapy was 57% in our overall pediatric cancer population. The prevention of patients against virus, vaccination of parents, and review of therapy plans might be scheduled in cancer centers.